About
Michael Cordingley, PhD is a senior biopharma R&D executive and virologist with more than 30 years of experience in antiviral drug discovery and development. Public company bios identify him as Chief Scientific Officer at Transposon Therapeutics and Senior Virology Adviser at Antiva Biosciences, following prior leadership roles at Boehringer Ingelheim Canada, Merck Research Laboratories, Bristol-Myers Squibb, NIH, and McGill University. His profile is that of a scientific/operator leader in biotech rather than a fund manager or documented personal investor.
Areas of interest
biotechvirologyinfectious diseaseantiviral drug discoveryneurodegenerative diseaseautoimmune diseaseage-related diseasedrug development